Overview of Letiz

Letiz is a medicine containing the active ingredient Levocetirizine, a synthetic compound utilized for the symptomatic management of allergic conditions. It is administered through the oral route and functions as a highly specific antihistamine.

Property	Description
Active ingredient	Levocetirizine
Form	Oral tablets, oral solution, or oral drops
Pharmacological class	Second-generation H1-receptor antagonist
General use	Symptomatic relief for allergic conditions
Origin	Synthetic compound (R-enantiomer)

What Type of Medicine is Levocetirizine?

Levocetirizine, the active substance in brands like Letiz, is classified as a Selective peripheral H1-receptor antagonist, belonging to the larger group of second-generation antihistamines. This pharmacological class is defined by its ability to selectively bind to H1 receptors predominantly located in the body's tissues. This means the compound primarily focuses its activity on the periphery, where allergic symptoms are expressed, a property clinically recognized as supporting a different profile compared to older agents.

Levocetirizine: Composition, Origin, and Available Forms

The active ingredient in Letiz is Levocetirizine, a single, chemically resolved substance that is the potent R-enantiomer of Cetirizine. This synthetic compound is prepared as a single active ingredient product, distinguishing it from combination remedies. Levocetirizine is typically made available for administration in several oral dosage form(s), including common presentations such as film-coated tablets, as well as liquid preparations like oral solutions or drops, which may be preferred for patient groups like children.

What is the General Purpose of Levocetirizine?

The general purpose of Levocetirizine is to provide effective symptomatic relief for the physical manifestations of various allergic conditions and hypersensitivity reactions. By acting as a Histamine antagonist, the medicine mitigates the discomfort—such as chronic itching or an acute allergic flare-up—that arises when the body releases histamine in response to an allergen. The drug's mechanism is extensively supported by clinical consensus to interrupt the core allergic cascade, thereby contributing to the overall management of allergic discomfort.

What side effects are possible with Letiz?

Possible side effects and safety information

The safety profile of Letiz (Levocetirizine) is categorized based on clinical trials and regulatory post-marketing surveillance, consistent with official government documents.

Adverse reactions are classified by frequency and the body system affected (System-Organ-Class or SOC).

Documented Adverse Reactions

The most frequently documented side effects, classified as Common (ge 1/100 to <1/10), typically relate to the nervous system and general state. These include somnolence (drowsiness), fatigue, and dry mouth, as well as nasopharyngitis and pharyngitis.

Reactions reported less frequently or through post-marketing surveillance (often classified as Not Known frequency) cover a broader range of SOCs, including Psychiatric Disorders (e.g., aggression, suicidal ideation, depression), Nervous System Disorders (e.g., convulsions), and Gastrointestinal Disorders (e.g., nausea, vomiting).

Serious Adverse Reactions and Constraints

Serious adverse reactions documented in regulatory sources include anaphylaxis (severe allergic reaction), urinary retention, and the post-marketing observation of suicidal ideation. These are considered rare but clinically significant safety events.

Use of Levocetirizine is contraindicated in patients with known hypersensitivity to the drug or its derivatives, and in individuals with end-stage renal disease (Creatinine Clearance < 10 mL/ min). Dose adjustment is necessary for older adults and others with less severe renal impairment.

One exposure-related safety pattern is the reported occurrence of severe generalized pruritus (itching) that may appear days after stopping the medicine, particularly following long-term use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Letiz (Levocetirizine) strictly through effects on the Central Nervous System (CNS) and mandated supportive care.

Documented Clinical Manifestations

Overdose presentations are officially differentiated by age. The principal documented sign of overdose in adults is somnolence (drowsiness). For children, the official labeling notes a distinct pattern where initial symptoms may involve agitation and restlessness, which is subsequently followed by somnolence. Reports involving exposures exceeding five times the maximum recommended daily dose have been associated with signs such as confusion, stupor, and rapid heartbeat (tachycardia).

Emergency Response and Supportive Management

In the event of a suspected overdose, immediate medical attention must be sought. Official regulatory guidance recommends contacting a Poison Control Center for immediate assistance.

Management is strictly symptomatic and supportive, as the prescribing information explicitly states there is no known specific antidote to Levocetirizine dihydrochloride. Regulatory documents also specify a critical constraint for treatment: the substance is not effectively removed by dialysis. Gastric lavage may be considered as a supportive measure following a recent ingestion of a significantly large dose.

Therapeutic Uses of Letiz

What Letiz Treats: Main Uses and Benefits

Letiz (which corresponds to the drug substance Tasimelteon) is a treatment utilized in the management of specific sleep-wake cycle conditions. The medication is prescribed to help address certain disorders that affect the natural timing of the body's sleep and wake periods.

Quick Facts

Addresses: Non-24-Hour Sleep-Wake Disorder (Non-24) in adults.
Assists with: Nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS) in certain patient populations.

Its primary role is to serve as an approved therapy within the context of these specific conditions. It is important to note that a healthcare provider must determine if this medication is an appropriate component of a patient’s overall therapeutic regimen.

Eligibility and Restrictions for Use

The official eligibility profile for Letiz (containing the active substance Tasimelteon) establishes strict criteria for its use, primarily based on age, medical condition, and organ function, as defined by regulatory documents.

Populations Not Eligible for Use

Classification	Population/Condition	Restriction Basis
Contraindicated	Known hypersensitivity to the active substance or excipients	Explicit exclusion (EMA)
Contraindicated	Hereditary disorders like galactose intolerance (due to excipients)	Excipient-based restriction (EMA)
Not Recommended	Patients with severe hepatic impairment (Child-Pugh Class C)	Lack of safety data/risk (FDA/EMA)

Age and Condition Eligibility

Eligibility Group	Condition	Status in Regulatory Labeling
Adults (age 18+)	Non-24-Hour Sleep-Wake Disorder	Approved for use (FDA/EMA)
Pediatric (age 3–15)	Nighttime sleep disturbances in SMS	Approved for use (FDA)
Pediatric (<3 years)	All indications	Safety and effectiveness not established (FDA)
Older Adults (>65)	All indications	Use permitted, but increased exposure requires caution (FDA/EMA)

Use During Pregnancy and Lactation

Regulatory agencies advise that use during pregnancy should generally be avoided (EMA) or restricted only to cases where the potential benefit clearly justifies the potential risk (FDA). For lactation, a choice must be made between discontinuing treatment or discontinuing breastfeeding [DailyMed].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Letiz (Tasimelteon) is officially defined by its dependence on hepatic metabolism and its potential for additive central nervous system (CNS) effects. All restrictions and statements are derived strictly from official regulatory labeling.

Interacting Medicinal Product Categories

Strong CYP1A2 Inhibitors: Co-administration with these drugs (e.g., Fluvoxamine) must be avoided. This restriction is due to a documented pharmacokinetic interaction that results in a significant increase in Tasimelteon plasma exposure, reaching up to 6.5-fold.
Strong CYP3A4 Inducers: Co-administration with these drugs (e.g., Rifampin) must also be avoided. This interaction substantially decreases Tasimelteon exposure, resulting in an up to 89% reduction, which may compromise efficacy.
Other CNS Depressants and Alcohol: Caution is advised with concomitant use of substances like Ethanol because this combination may result in a trend toward additive CNS effects on psychomotor performance.
Exposure-Altering Substances: Smoking is documented to decrease Tasimelteon exposure by approximately 40% through moderate enzyme induction. Furthermore, certain Beta-Adrenergic Receptor Antagonists may reduce the efficacy of Tasimelteon.

Timing and Population Constraints

Administration Timing: Letiz must be administered without food. This is a mandatory rule to prevent lowered drug concentrations, which are documented when the medicine is taken with a high-fat meal.
Population Notes: Use is not recommended in patients with Severe Hepatic Impairment (Child-Pugh Class C). This restriction is in place because the effect of severe liver compromise on the drug's systemic exposure is officially unknown.

Mechanism of Action

How Letiz Works: Mechanistic Domains and Physiological Effects

Targeting the Peripheral Histamine H1 Receptor

This domain focuses on the selective, high-affinity antagonism of the peripheral Histamine H1 Receptor ( H1R). The drug acts as an inverse agonist, stabilizing the H1R in its inactive state to physically block histamine binding and reduce its constitutive activity. This molecular action modifies early signaling steps and shapes the resulting downstream physiological response to histamine.

Modulating Vascular Permeability and Smooth Muscle Dynamics

The direct consequence of H1R blockade is the interruption of the G q/11-protein signaling cascade, which prevents the rise of intracellular calcium that normally causes cellular changes. This mechanism results in attenuation of the impact of excessive mediator activity by inhibiting the contraction of microvascular endothelial cells against histamine-induced leakage, resulting in the maintenance of capillary integrity and smooth muscle tone.

️ Modulating Inflammatory Cell Recruitment

Beyond immediate receptor blockade, the drug engages mechanisms that influence the allergic inflammatory pathway by inhibiting the activation and chemotaxis (migration) of key inflammatory cells, such as eosinophils. This supplementary action extends the modulation of processes driven by distinct signaling patterns, which results in attenuated accumulation of cells that release secondary inflammatory substances.

Dosage and Administration Information

How to Use Letiz

Letiz, which corresponds to the active substance Tasimelteon, is administered exclusively through the oral route as a daily regimen intended for chronic use. The medicine is available as 20 mg hard capsules and a 4 mg/mL oral suspension. Administration must maintain a strict, precise schedule to align with the intended use pattern.

The standard administration schedule mandates a single dose of 20 mg taken one hour prior to bedtime at the same time every night. Critically, the dose must be taken without food. The two available dosage forms—capsules and oral suspension—are officially not substitutable for one another.

Population Group	Labeled Dosing Regimen	Contextual Instruction
Adults (Standard)	20 mg once daily.	Must be taken one hour before bedtime, without food.
Pediatric Patients (3 to 15 years)	Weight-based (0.7 mg/kg or 20 mg) via oral suspension.	Use is not recommended in patients with severe hepatic impairment.

For administration, capsules must be swallowed whole and should not be crushed or chewed. If the oral suspension is used, it must be shaken well for at least 30 seconds before every administration. In the event an intended dose is missed, the dose should be skipped for that night, and the patient must return to the regular schedule the following evening. This protocol establishes definitive rules for consistency and administration method.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Letiz (Tasimelteon)

The active substance tasimelteon was studied for clinical trials and long-term follow-up research. These studies explored symptom patterns related to two specific sleep-wake conditions.

Evidence for Non-24-Hour Sleep-Wake Disorder

Research for Non-24-Hour Sleep-Wake Disorder (Non-24) was conducted using large-scale, controlled studies. The primary studies were randomized and placebo-controlled and involved totally blind adults who have no light perception. Researchers examined two main types of outcomes: the timing of the body's internal clock, known as circadian entrainment, measured using a biological marker; and changes related to sleep, such as nighttime sleep duration and daytime sleep duration (naps).

Findings described patterns observed in the studies, reporting that the measurement for circadian entrainment was aligned with the 24-hour cycle more often in the active treatment group compared to the placebo group. Measures related to nighttime sleep duration and daytime sleep duration were reported in the observed active treatment group compared to the placebo group, particularly on days and nights where symptoms were most noticeable.

Evidence for Sleep Disturbances in Smith-Magenis Syndrome

Evidence describing the use of Letiz for sleep disturbances associated with the rare genetic condition Smith-Magenis Syndrome (SMS) was evaluated in a smaller, short-term, controlled crossover study. The study evaluated both children (as young as 3 years) and adults with a confirmed diagnosis of SMS. The primary research examined outcomes related to physical discomfort and daily functioning, focusing on patient-reported outcomes describing average sleep quality and total sleep time at night.

Findings described that measured changes in sleep quality and total sleep time were observed during the active treatment period of the crossover study compared to the placebo period, based on information recorded in daily diaries kept by the patients or their caregivers.

Evidence Consistency and Research Gaps

One key limitation is that the results apply only to the studied populations. For Non-24, this means the results apply only to totally blind adults, and research evidence remains insufficient for sighted individuals or those with partial light perception. Comparative evidence against other treatments is limited, as the primary studies for both indications used a placebo as the comparison.

Key Studies & References Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder (SET Trial) (NCT01163032)

Frequently Asked Questions (FAQ)

Common questions about Letiz (FAQ)

Q: How quickly should someone expect Letiz to start working?

Studies and official information indicate that the medicine generally has a rapid onset of effect. Maximum plasma concentrations in the body are typically achieved in approximately 0.75 to 1 hour after taking an oral dose. The maximum plasma concentration is a measure related to the time the medicine becomes available to act in the body.

Q: Do the side effects of Letiz usually go away over time?

Common side effects, such as drowsiness and fatigue, are generally reported in regulatory documents as mild to moderate in intensity. Official product information also reports a rare side effect of intense itching (pruritus) that may occur days after discontinuing the medicine, particularly following long-term use.

Q: Is it common to feel tired when first starting Letiz?

Yes, somnolence (drowsiness) and fatigue are among the most frequently documented side effects. According to the official product information, some evidence indicates these events are reported more frequently in the first month of observation after starting treatment.

Q: How long does it take for Letiz to be cleared from the body?

The elimination half-life is the measure of how long it takes for half of the drug to be eliminated from the bloodstream. For Letiz, the average half-life in adults is approximately 7 to 8 hours.

Q: Are there any known interactions between Letiz and alcohol?

Caution is advised with the concomitant use of alcohol (Ethanol) and other Central Nervous System (CNS) depressants. Regulatory warnings indicate this combination may result in additive reductions in alertness and may affect psychomotor performance, such as concentration.

Q: What is the main difference between Letiz and similar medicines?

Letiz is officially classified as a second-generation selective H1-receptor antagonist. It is distinct because it is specifically the active R-enantiomer of cetirizine. This characteristic is noted for its high affinity for the H1-receptor and a low potential for causing significant sedative effects.

Q: Is Letiz considered a long-term treatment or short-term?

The medicine is indicated for the symptomatic treatment of persistent allergic conditions, such as perennial allergic rhinitis and chronic idiopathic urticaria. Regulatory documents describe it as often being used as a daily regimen intended for chronic use.

Q: Has Letiz been studied in children or adolescents?

Yes, the medicine is approved and has established dosing for children as young as six months for certain allergic conditions and for adolescents 12 years and older. Specific dosing information for these age groups is available in the regulatory documents.

Q: Can Letiz cause trouble sleeping?

While the most common nervous system effect reported is drowsiness, psychiatric adverse reactions have also been documented. Insomnia (trouble sleeping) and nightmares have been reported as less common side effects in the official product information.

Q: What kind of research has been done on Letiz?

The research evidence for the medicine primarily comes from randomized, controlled studies. These studies examine its effectiveness in relieving symptoms associated with seasonal and perennial allergic rhinitis and chronic idiopathic urticaria (hives) in various adult and pediatric populations.

Q: Why is Letiz sometimes prescribed instead of older generation drugs?

As a second-generation antihistamine, Letiz is associated with a lower potential for causing drowsiness and a reduced impact on mental alertness when compared to some older antihistamines. This profile is associated with its classification as a second-generation antihistamine.

Q: What happens if Letiz is stopped suddenly? (Informational)

Official post-marketing surveillance reports a rare, sometimes severe, reaction of intense itching (pruritus) which can appear days after stopping the medicine, particularly following long-term use.

Q: What is the connection between Letiz and the liver?

The drug is eliminated mainly by the kidneys, with very little metabolized by the liver. However, use is not recommended in patients with severe hepatic impairment (severe liver problems). This restriction is in place because there is insufficient data on the safety and effect of the drug in this specific population.

Q: Does Letiz have any risk of addiction or dependence?

Official regulatory documents do not list addiction, abuse potential, or the risk of dependence as known risks or required warnings for this medicine. It is not classified as a controlled substance.

Q: Are there any warnings about driving or operating machinery while taking Letiz?

Warnings in the official labeling advise caution with activities requiring complete mental alertness, such as driving or operating machinery, because the medicine can cause somnolence, dizziness, or fatigue in some individuals.

Q: Can Letiz affect a person's mood or behavior?

Rare psychiatric side effects have been reported in official product information. These include changes in mood and behavior such as agitation, aggression, confusion, depression, and hallucinations. Suicidal ideation has also been noted in rare post-marketing reports.

Q: Does Letiz work for all types of allergic conditions?

The medicine is officially indicated for the symptomatic relief of specific conditions: seasonal allergic rhinitis, perennial allergic rhinitis, and uncomplicated skin manifestations of chronic idiopathic urticaria (hives).

Q: Can I take Letiz if I have a history of heart problems?

Regulatory documents generally describe the drug as having a low potential for significant cardiovascular effects. However, in rare instances, fast or irregular heartbeat has been reported in post-marketing surveillance.

Q: Are there interactions with herbal remedies or supplements?

While specific interaction studies with many herbal remedies have not been performed, caution is generally advised when combining Letiz with any product, including herbal supplements, that may cause Central Nervous System (CNS) depression (such as drowsiness).

Q: What if I have an existing known allergy to similar compounds (drug derivatives)?

The medicine is contraindicated if there is a known hypersensitivity (allergy) to the active substance, any of its components, or to cetirizine (its parent compound). Cross-reactivity with similar chemical derivatives has been reported in official documents.

Q: Does Letiz have any common effects on weight or appetite?

According to official clinical trial data, weight gain or increased weight has been reported as an uncommon side effect. This means it was observed in less than 1% of patients studied.

How should Letiz be stored and disposed of?

How to Store and Dispose of Letiz

The storage and disposal requirements for Letiz (Levocetirizine Dihydrochloride) are officially defined to maintain drug integrity and ensure safe environmental handling.

Storage Requirement	Details
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep the container tightly closed in its original packaging. Protect from excessive heat and moisture.
Child Safety	Mandatory to keep out of the sight and reach of children.
Oral Solution Stability	The oral solution/drops must be discarded after 3 months from the first opening of the bottle.
Disposal Rule	Dispose of unused or expired medicine according to local regulations. The product must not be thrown away via wastewater.

Letiz